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Activation of the immune system is a multistep process. 
The transcription factor nuclear factor-kappa B (NF-
kB), has been one of the most widely studied molecules 
in the immune system, as it is activated by a variety of 
stimuli and it in turn controls diverse genes and bio-
logical responses. It is an evolutionarily conserved 
molecule that coordinates the organism’s response to 
infection, stress and injury. It plays a major role in 
the induction of pro-inflammatory genes and affects 
the various cells involved in immune response as well 
as affects the generation of innate and adaptive immun 
response. It is also a target for drugs used in treat-
ment of various inflammatory diseases.  
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THE main function of the immune system is recognition 
and control of invading pathogens. Recognition f pathogens 
by innate or adaptive immune receptors leads to activation 
of immune cells, e.g. macrophages, dendritic cells and 
lymphocytes. The signal generated after recognition of a 
pathogen is communicated to the nucleus, resulting in en-
hanced expression of effector molecules such as cytokines 
and adhesion molecules. This process depends on activation 
of various inducible transcription factors, among which 
the nuclear factor-kappa B (NF-kB) transcription factors 
play an evolutionarily conserved and critical role in triggering 
and coordinating both innate and adaptive immune res-
ponses1. 
 NF-kB is a collective name for inducible dimeric tran-
scription factors. They are made up of members of the 
Rel family of DNA binding proteins that recognize a 
common sequence motif. It is a ubiquitous transcription 
factor. Nevertheless, its properties seem to be most exten-
sively exploited in cells of the immune system2. NF-kB 
plays a crucial role in immune and inflammatory responses 
through the regulation of genes encoding pro-inflamma-
tory cytokines, adhesion molecules, chemokines, growth 
factors and inducible enzymes such as cyclo-oxygenase 2 
(COX2) and inducible nitric oxide synthase (iNOS)3–5.  
 NF-kB can be activated within minutes by a variety of 
stimuli, including inflammatory cytokines such as TNF-a
and interleukin-1, T-cell activation signals, growth fac-
tors and stress inducers6. The generation of mouse mod ls 
with defective NF-kB activation orlack of essential NF-
kB subunits, such as Rel-A (also known as p65), has re-
vealed an important role of NF-kB in innate and adaptive 
immunity, inflammation and lymphoid organ develop-
ment7,8. Another exciting development has been the demon-
stration, that in certain situations, NF-kB acts as an anti-
apoptotic protein. Furthermore, several studies have focused 
on other diverse functions of NF-kB, which clearly illus-
trate its ‘good and evil’ aspects, whereby NF-kB is re-
quired for immunological functions but is detrimental 
when it is dysregulated. This review aims to highlight the 
above functions of this intriguing molecule. 
Structure, functions and signalling pathways of 
NF-kB 
Structure 
NF-kB was first identified as a regulator of the expression 
of the kappa light-c ain gene in murine B-lymphocytes, 
but has subsequently been found in many different cells. 
NF-kB represents a group of structurally related and evo-
lutionarily conserved proteins that belong to the Rel family 
and are regulated via shuttling from the cytoplasm to the 
nucleus in response to cell stimulation9. Mammals express 
5 Rel (NF-kB) proteins that belong to two classes. The 
first class includes Rel A (p65), c-Rel and Rel-B proteins 
that are synthesized as mature prod cts and do not require 
proteolytic processing. The second group is encoded by 
the NF-kB1 and NF-kB2 genes, whose products are first 
synthesized as large precursors, p105 and p100, respecti-
vely, that require proteolytic processing to produce the 
mature p50 and p52 NF-kB proteins10 (Table 1).  
 
Table 1. Members of the NF-kB/rel and IkB families of proteins 
NF-kB/Rel proteins  Ik-B proteins 
 
Relish (971) Ik-B-g (607)  
Dif (667) Bcl-3 (421)  
Dorsal (678) IkB-e (500)  
Rel B (558) IkB-a (317)  
c-Rel (587) IkB-b (359)  
p-65 (550) Cactus (460)  
P105/p50 (940)  
Values in brackets represent number of amino acids in each protein.
REVIEW ARTICLES 
 
CURRENT SCIENCE, VOL. 90, NO. 4, 25 FEBRUARY 2006 520
Table 2. Functions and characteristics of NF-kB/rel and IkB families of proteins 
NF-kB subunit   Size and special characteristics          Functions 
 
RelA (p65) 65 kDa Lack of Rel A causes embryonic lethality and liver degeneration  
   in knockout mice due to apoptosis of fetal hepatocytes 
RelB 68 kDa  
 Does not possess phosphokinase A (PKA) phosphory-  Essential for normal hemopoietic and immune cell function 
   lation site, but an additional N-terminal leucin-  
   zipper-like region, which affects its transcriptional  
  activity  
NF-kB1 (p50; p105)  50 kDa   
 Synthesized as the precursor IkB protein p105 Mice lacking p50 are immunodeficient, but o herwise develop  
    normally to adulthood 
 p50 does not possess transactivation domain B-cells from p50 knockout mice show abnormal mitogen  
    responses and antibody production  
   Development and differentiation of dendritic cells, and a  
    mutation disrupting relBimpairs antigen presentation 
NF-kB2 (p52; p100) 52 kDa  Essential for normal hemopoietic and immune cell function 
 Synthesized as the precursor IkB protein p100 
  p52 does not possess transactivation domain  
c-Rel 69 kDa c-Rel-deficient mice develop normally, their mature B and T 
    cells exhibit selective activation defects in response to certain 
    mitogenic stimuli 
 
 
 
 
Figure 1. Structure of Rel family transcription factors. Adapted from 
www.ncbi.nlm.nih.gov/entrez/query.fcgi 
 
 
 NF-kB dimers containing Rel A or c-Rel are held in the 
cytoplasm through interaction with specific inhibitors, the 
IkBs. The IkBs are also members of a gene family that 
contains seven known proteins, IkBa, IkBb, IkBe, IkBg, 
Bcl-3 and the precursor Rel proteins p100 and p105. I-
terestingly, p100 may serve both as an IkB and a specific 
heterodimeric partner for Rel B, such that its processing 
results in the release of p50 : Rel B heterodimers (Table 
2). The IkBs are characterized by the presence of multiple 
ankyrin repeats and interact with NF-kB via Rel homology 
domain (RHD). The RHD serves several functions: it is 
the dimerization and DNA-binding domain for this class 
of proteins, it contains the nuclear localization sequence 
(NLS), and most important for its regulation it is the site 
for binding of NF-kB inhibitors the IkBs10–12 (Figure 1). 
NF-kB activation by the IkB complex 
IkBs are a small family of related proteins with a core 
consisting of six or more ankyrin repeats, an N- erminal 
regulatory domain and a C-terminal domain that contains 
a PEST motif. The IkBs undergo rapid ubiquitin-depen-
dent degradation after exposure to a variety of agonists, 
which activate the IkB (IKK) complex10–12 (Figure 2).  
 IKK is composed of three subunits, IKKa (IKK1), 
IKK b (IKK2), and IKKg (also known as NF-kB essential 
modulator, NEMO)12. IKKa and IKKb are the catalytic 
subunits of the complex, sharing 52% overall sequence 
identity and 65% identity in their catalyti  domains. 
IKK a (previously identified as a protein kinase with un-
known function named conserved helix– oop–helix ubi-
quitous kinase (CHUK)) was initially isolated as a protein 
that interacts in yeast cells with ano er protein kinase 
called the NF-kB-inducing kinase (NIK). NIK is so called 
due to its ability to potently stimulate NF-kB activity in 
transiently transfected cells. The third subunit, IKKg/ 
NEMO, is the regulatory subunit and is not related to the 
catalytic subunits. IKKa and IKKb have similar primary 
structures and contain protein kinase domains at their N-
t rmini, and leucine zippers (LZ) and helix–loop–helix 
(HLH) motifs in their C-terminal portions. IKKg does not 
contain a recognizable catalytic domain, but is composed 
mo tly of three large a-helical regions, including an LZ. 
IKK a and IKKb can form homodimers and heterodimers 
(or tetramers) in vitro, and purified recombinant forms of 
each can directly phosphorylate IkBa and IkBb at the 
proper sites. Biochemical analysis of two human cell lines 
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Figure 2. Schematic representation of pathways of activation and regulation of IkB. Adapted from refs 1, 2, 5, 6. 
 
 
indicates that the predominant form of IKK is an IKKa : 
IKK b heterodimer associated with eithera dimer or trimer 
of IKKg. The IkBs bind to NF-kB dimers and sterically 
block the function of their NLSs, thereby causing their 
cytoplasmic retention10–12. 
 In addition to IKKa, IKKb, NIK, IKBa and NF-kB/ 
RelA, IKK complex contains a fourth pro ein, a 150-kDa 
IKK complex-associated protein called IKAP (IKK com-
plex-associated protein). It is proposed to be involved in 
IKK activation and functions as a scaffold protein due to 
its ability to assemble IKKa, IKKb, NIK, and NF-kB : 
IkB. However, since IKAP is not readily detected as a 
constituent of the IKK complex, its physiological signifi-
cance and function are not yet clear. It also remains to be 
determined whether IKAP is required for IKK activation 
at all and, if so, whether it is involved in responses to all 
NF-kB-activating stimuli or to only a subset of them. It is 
possible that while IKKg, which is a stoichiometric com-
ponent of IKK, is required for IKK activation by all stimuli, 
proteins like IKAP may connect IKK to a specific set of 
upstream activators. Furthermore, sequence analysis sug-
gests that IKAP is the human homologue of one of the 
components of the yeast transcriptional elongation ‘Elon-
gator’ complex. Thus, IKAP is most probably a nuclear 
protein and, thus, is unlikely to serve as a component of 
the cytoplasmic IKK complex11–14. 
 Stimulation by a diverse array of pathogens and other 
inducers, including viruses, cytokines, and stress-induc-
ing agents led to activation of signalling cascades that 
culminate with the activation of the IKK complex and 
phosphorylation of the IkB inhibitor. NF-kB DNA bind-
ing subunits are released and translocated to the nucleus, 
where they transactivate NF-kB responsive genes. Target 
genes are selectively regulated by the distinct transcrip-
tional activation potential of different NF-kB subunit 
combinations15,16. The consensus pathway for NF-kB acti-
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vation in response to pro-inflammatory stimuli such as 
TNF-a and IL-1b has been extensively characterized. 
These cytokines act through distinct signalling pathways
that converge on the activation of an IKK; the subsequent 
phosphorylation of IkB molecules targets them for degra-
dation by the proteosomes17.  
Regulation and function of IkB 
Potent NF-kB activators, such as TNFa and IL-1, cause 
almost complete degradation of IkBs (especially IkBa) 
within minutes. The mechanisms by which these highly 
diverse stimuli activate IKK are, however, poorly under-
stood. Structure prediction programs suggest the presence 
of numerous docking sites for interacting proteins on 
IKK a, IKKb, IKKg and IKAP, but the search for signallin  
molecules that directly dock to these sites is in its infancy. 
Mitogen-activated protein kinase/ERK kinase kinases 
(MAP3Ks), such as NIK and MEK kinase 1 (MEKK1), 
activate IKK when overexpressed. NIK may potentially 
interact with IKK through IKAP. However, there is little 
evidence till now that NIK or MEKK1 is a physiological 
IKK activator. In the case of IKKg (but not IKAP), genetic 
and biochemical data clearly show that IKKg is essential 
for IKK activation in response to at least six different 
stimuli, but it is not known with which upstream activators 
IKK g interacts18,19.  
 Studies using mouse mutants that lack either IKKa or 
IKK b have suggested that IKK b is far more important 
than IKKa for activation of the IKK complex in response 
to pro-inflammatory stimuli. Most interestingly, however, 
these experiments i dicate a new role for IKK a in con-
trolling the proliferation and differentiation of epidermal 
keratinocytes as well as affecting (directly or indirectly) 
other developmental decisions, including skeletal pattern-
ing. IKK a-deficient mice are born alive, but die within 
30 min. The mutant mice exhibit a plethora of develop-
mental defects, the most striking of which are their taut, 
thick skin, highly rudimentary limbs and tail, and shorter 
head. It turns out, however, that IKKa–/– mice do have 
limbs and a tail whose proximal elements are almost 
normal, but they are hidden under their thick ned skin. 
The distal elements of the limbs are mal-developed due to 
a defect in inter-digital apoptosis20,21. 
 Histochemical and microscopic examination of IKK a–/– 
skin reveals marked hyper-proliferation of the epidermal 
layer and almost complete absence of differentiation. Due 
to the absence of fully keratinized cells, the mutant skin 
appears to be rather sticky, which causes the limbs and 
tail to be ‘glued’ to the body instead of developing as 
well-separated outgrowths. Despite these marked alter-
tions in morphology, the activation of IKK by TNF, IL-1 
or lipopolysaccharide in the fibroblasts and liver of 
IKKa–/– mice seems to be normal. The loss of IKKb re-
sults in an expected phenotype, which confirms its impor-
tance for IKK activation by TNF and other pro-inflam-
matory stimuli. IKK b–/– mouse embryos die on day 12 to 
13 of gestation due to massive liver apoptosis. This phe-
notype is essentially identical to that of p65 (RelA)-
defici  mice, except that IKK b–/– mice die a day or two
earlier. This is probably due to the more severe decrease 
in NF-kB activity in IKK b–/– cells than in RelA–/– cells. 
Indeed, protein kinase and mobility shift assays7,21,22 indi-
cate that IKK b–/– cells are completely defective in activa-
tion of IKK and NF-kB in response to TNF or IL-1. 
 Despite the extensive sequence similarity between 
IKK a and IKKb and their tight association in most cell 
types, these two protein kinases play different regulatory 
and functional roles. IKK b is essential for IKK activation 
by pro-inflammatory cytokines and for IkB phosphoryla-
tion. Yet,IKK b does not have an essential role in embryonic 
development. The hepatic apoptosis in IKK b–/– embryos 
is simply due to a defect in NF-kB activation, which is 
required for protecting the liver from TNF-induced apo-
tosis. By contrast, IKK a is dispensable for IKK activtion 
or IkB phosphorylation in response to pro-inflammatory 
st muli, but plays an essential role in epidermal develop-
ment19. 
Functions of NF-kB 
NF-kB regulates the transcription of an exceptionally large 
number of genes, particularly those involved in immune 
and inflammatory responses. The regulation of inflam-
mation, cell proliferation and apoptosis is at the centre of 
understanding of many diseases such as rheumatoid ar-
thritis (RA), AIDS and cancer. It has become clear over 
the years that NF-kB is a pleotropic transcription factor 
involved in the inducible expression of a wide variety of 
genes, particularly those that promote cell growth and 
survival.  
NF-kB in apoptosis 
Apoptosis is an important process that regulates the de-
velopment and selection of T- and B-lymphocytes and is 
critical for the maintenance of immunological homeostasis 
in the periphery. The finding that NF-kB is activated dur-
ing or immediately before cell apoptosis under stimulato y
conditions, has led to the suggestion that the activation of 
NF-kB is strongly linked to inhibition of apoptosis23–25. 
In most cells, NF-kB activation protects the cell from 
apoptosis, through induction26 of survival genes such as 
TRAF1, TRAF2, c-IAP1, c-IAP2, IEX-IL, Bcl-xL and BfI-1/ 
A126. In vitro studies27, where loss of RelA renders em-
bryonic fibroblasts more susceptible to TNF-induced 
apoptosis and in vivo studies in which RelA–/– mice die as 
embryos as a consequence of TNF-mediated apoptosis in 
the livers of these animals, provide clear evidence for the 
role of NF-kB in preventing apoptosis28–30. In fact, NF-
kB binding sites have been identified in the promot rs of 
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interleukin-1b converting enzyme protease, c-myc and 
TNF-a genes, which are commonly involved in signal-in-
duced programmed cell death.  
 Although most studies link NF- B with prevention of 
apoptosis, numerous recent studies have clearly demon-
strated a pro-apoptotic role for NF-kB perhaps because it, 
along with AP-1, can induce FasL expression31. Treatment of 
human thymocytes and promyelocytic leukaemia cells 
with etoposide activates NF-kB and induces apoptosis32. 
Moreover, in other experimental systems, increased lev-
els of NF-kB activation during development of avian em-
bryos and in focal cerebral ischaemia have been correlat d 
with apoptosis, but it is difficult to determine whether the 
increased NF-kB activity observed is a cause or consequence 
of apoptosis. How does NF-kB particpate in a dual role, 
wherein it mediates both life and death signals in cells? It 
is possible that different NF-kB members mediate differ-
ent signals and that the role of NF-kB in apoptosis de-
pends on the cell type or the type of stimulation that 
determines which signalling pathways are activated25,33. 
NF-kB in development of immune system 
The availability of NF-kB–/– cells and NF-kB–/– mice has 
elucidated the role of specific NF-kB proteins in develop-
ment and function of immune cells. Initially, it was 
speculated as a key transcription factor for the develop-
ment of B cell, but now it has become more vident that 
it is also required for the development and function of 
many other cells, including T cells thymocytes, dendritic 
cells, macrophages and fibroblasts34,35. 
 The targeted disruption (or knockout) of the p65 com-
ponent of NF-kB is lethal because of the associated de-
velopmental abnormalities, whereas the lack of p50 
components results in immune deficiencies and increased 
susceptibility to infection36. As mentioned above, RelA is 
essential to prevent TNF-mediated apoptosis in the liver 
of developing foetus, but RelA is not required for the de-
velopment of T and B cells, as the transfer of foetal liver 
cells from RelA–/– mice to irradiated SCID mice leads to 
normal lymphocyte development. It appears that signalling 
through IKKb is essential to protect T cells from TNF-a 
induced apoptosis during development37. 
 Further, the role of NF-kB in T-cell development and 
selection is evident from the transgenic expression of a 
degradation-deficient form of IkBa in T cells. Because 
this mutant protein is not degraded in response to signals 
that activate NF-kB, it acts as a global inhibitor of this 
signalling pathway. Several groups have generated similar 
transgenic mice, and while there are some differences be-
tween these mice, their phenotyp s have included d-
creased thymic cellularity, reduced numbers of peripheral 
CD8+ T cells, and increased levels of apoptosis38,39.  
 Although individual NF-kB proteins are not essential 
for the development of conventional, mature B cells, re-
cent gene knockout studies have provided evidence that a 
deficiency in B cells occurred when the genes NF-kB1 
and NF-kB2 and c-Rel were disrupted40. In these models, 
B-cell maturation is blocked at the immature stage. The 
mechanism behind immaturity is not known. Perhaps NF-
kB activation mediated by TNF superfamily member 
BlyS, is dysregulated in these mice. BlyS (B-lymphocyte 
stimulator) is a key molecule in B-cell proliferation41.  
 The role of NF-kB in the development of dendritic 
cells is illustrated by the lack of CD8a– and thymic den-
dritic cells in RelB–/– mice42. Further, absence of NF-kB2 
leads to lack of follicular dendritic cells in mice. Although 
 lack of thymic den ritic cells in RelB–/– mice is an i-
direct consequence of a defect in thymic epithelia, the 
lack of other dendritic cell populations in RelB–/– and NF-
kB2–/– mice could be due to specific blocks in the devel-
opment or maturation processes that give rise to these 
subsets43. In fact, previous studies have shown that in-
hibitors of NF-kB activation block maturation of dedritic 
cells44. Macrophages from RelB–/– mice are deficient in 
their ability to produce TNF-a and can produce normal 
levels of IL-6, IL-10, and IL-12, but overproduce IL-1b. 
Macrophages from c-Rel–/– mice overproduce GM-CSF 
and IL-6, but have a reduced ability38 to produce TNF-a. 
The exact role of NF-kB family members in the develop-
ment of cell lineages r mains to be defined an  future 
studies may provide answers to these crucial issues.  
NF-kB in innate immunity 
The classical NF-kB pathway, based on IKKb-dependent 
IkB degradation, is es ential for innate immunity. The acti-
vation and nuclear translocation of NF-kB is associated 
with increased transcription of a number of different 
genes, including those coding for chemokines (IL-8), ad-
hesion molecules (endothelial leukocyte adhesion mole-
cule, vascular cell adhesion molecule, and intercellular 
adhesion molecule), and cytokines (IL-1, IL-2, TNF-a, 
and IL-12). These molecules are important components of 
the innate immune response to invading microorganisms 
and re required for migration of inflammatory and pha-
gocytic cells to tissues. The activated phagocytic cells 
kill, ingest and degrade bacteria, and eventually present 
bacterial antigens once they re-migrate to secondary lym-
phoid organs45. 
 Mycobacterium tuberculosis, Borrelia burgdorferi and 
Ne sseria gonorrhea and bacterial products such as LPS 
and Shiga toxin activate NF-kB in macrophages as well as 
other cell types46–48. Enteroinvasive bacteria activate NF-
kB in intestinal epithelial cells, a process which leads to 
increased production of inflammatory mediators such as 
chemokines (MCP-1 and IL-8) as well as TNF-a, inter-
cellular adhesion molecule, and cyclooxygenase-2. Scrub 
yphus, Chlamydia pneumoniae and Helicobacter pylori 
also lead to NF-kB-dependent induction of chemokines49.  
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 NF-kB-dependent responses are not restricted to bacteria, 
even protozoan parasite Trypanosoma cruzi can activate 
NF-kB on invasion of endothelial cells. There are also in-
direct pathways that le d to NF-kB activation, like release 
of IL-1 by pulmonary epithelial cells on infection with M. 
tuberculosis, which in turn activates the NF-kB path-
way49. Though it has been recognized for long that many 
bacterial products can activate NF-kB, identification of 
Toll-like receptors (TLRs) as specific pattern recognition 
molecules and the recognition that stimula ion of TLRs 
leads to activation of NF-kB has improved our under-
standing of how different pathogens activate NF-kB. 
Moreover, adjuvants used to boost immune response are 
also potent TLR agonists and therefore, activators of NF-
kB. TLRs are widely distributed, and are mainly present 
on accessory cells (macrophage, dendritic cell, B cell), 
however, there is evidence that TLRs are also present on 
T and NK cells50.  
 Initial studies identified TLR4 as the recptor for the 
LPS component of Gram-negative bacteria, but later res-
piratory syncytial virus and heat shock proteins wer  also 
shown to be a ligands for TLR4. TLR2 recognizes a larger 
variety of microbial products, including peptidoglycans 
and lipoproteins. TLR5 recognizes bacterial flagellin, 
TLR9 recognizes bacterial DNA, and TLR3 double-stran-
ded RNA. TLR signalling leads to increased expression 
of a number of genes regulated by NF-kB, including cyto-
kines, co-stimulatory molecules, nitric oxide, and suscep-
tibility to apoptosis as well as an autocrine increases in 
Toll expression51,52. The activation of macrophages to pro-
duce reactive oxygen and nitrogen intermediates is important 
in the control of many bacterial and parasitic infections. 
This is a complex process in which IFN-g is important for 
the activation of macrophages, but alone is not sufficient 
to activate macrophages to kill intracellular organisms. 
Additional cofactors such as TNF-a, LPS or signalling 
through CD40, are required to provide a second signal for 
macrophage activation. These second signals activate NF-
kB, and it has been shown that the induction of inducible 
nitric oxide synthase is regulated by NF-kB and that c-Rel 
is involved in this process52. 
 IL-12 is one of the most important cytokines involved 
in the activation of innate and adaptive responses to intra-
cellular infections. Its production in response to numerous 
intracellular organisms leads to the innate activation of 
NK cells, and enhances th ir cytolytic activity and produc-
tion of IFN-g. The link between IL-12 and NF-kB family 
of transcription factors wa  shown by studies in which the 
IL-12 p40 promoter was found to have NF-kB binding 
sites. Using macrophages from NF-kB–/– mice, researchers 
have shown that c-Rel and Rel-A are both important in 
the LPS-induced production of IL-12 by macrophages, al-
though NF-kB1 and NF-kB2 or RelB appear to have no 
major role in the ability of macrophages to respond to 
LPS. Studies have shown that c-Rel also plays a role in 
the ability of CD8a+ dendritic cells to make p35, but not 
p40. Whether different stimuli that induce IL-12 have differ-
ent requirements for specific NF-kB members is unknown, 
but recent studies indicate that there are c-R l-indepen-
dent pathways49 that lead to the production of IL-12. 
 Although monocytes and macrophages constitute a major 
arm of the innate immune system, there are other cell 
ypes which play an important role in the initial recogni-
tion of many pathogens a d may also provide effector ai-
vities. Nonimmune cells such as fibroblasts, endothelial 
and epithelial cells are also capable of responding to 
pathogens by activa ing NF-kB. Recently, it has been 
shown that fibroblasts re pond to necrotic cells in a 
TLR2-dependent fashion to activate NF-kB and the pro-
duction of chemokines. The latter studies provide a mecha-
ism that allows the immune system to recognize the 
presence of pathogens that cause cellular necrosis52. 
 The ability of neutrophils, mast cell  and eosinophils to 
recognize a diverse array of pathogens is thought to rep-
resent an important first line of defence against infectio . 
However, little is known about the role of NF-kB in the 
regulation of these innate responses. Recent data suggest 
that TNF-a-mediated activation f NF-kB delays neutro-
phil apoptosis and thus provides survival signal to neutro-
phils. This allows neutrophils to mediate their antimicro-
bial activities at the local site. NF-kB is also involved in 
the ability of mast cells to make the T-cell and mast-cell 
growth factor IL-9 and their expression34,45 of TLR4. 
 Although pathogens can stimulate activation of NF-kB, 
other immune molecules associated with innate immu ity 
also activate NF-kB. IL-1, IL-18, TNF-a, and signalling 
through CD28 lead to activation of NF-kB, and these sig-
nal  can augment the innate ability of NK cells to produce 
IFN-g. Since all of these cofactors are a sociated with ac-
tivation of NF-kB and there are NF-kB sites in the pro-
moter for IFN-g, it is likely that maximal activation of 
NK cells to produce IFN-g would be dependent on NF-
kB. This argument is supported by studies35 in which NK 
c lls from mice which lack RelB have a defect in their 
a ility to produce IFN-g. 
 Together, the above evidence associates activation of 
NF-kB with initial recognition of multiple pathogens, micro-
bicidal mechanisms of macrophages, production of multi-
ple p o-inflammatory cytokines, and activation of NK 
cells to produce IFN-g.  
NF-kB in adaptive immunity  
Many of the events that are important in triggering innate 
immune response to infection are also important for the 
development of protective T-c ll responses. Thus, the 
abilities of accessory cells to present antigen provide co-
stimulation, and produce cytokines in r ponse to infection 
are critical to the subsequent adaptive immun  response. 
The previous section highlighted the role of NF-kB in the 
innate production of IL-12, which is critical to direct the 
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development of T-cell responses dominated by the pro-
duction34 of IFN-g.  
 Additional studies have shown a role for NF-kB in 
other accessory cell functions involved in adaptive immunity. 
For example, RelA is required by embryonic fibroblasts 
to express optimal levels of major histocompatibility 
complex class-I and CD40 molecules, that help in the de-
velopment of CD8+ T-cell responses. Chemical inhibitors 
of NF-kB activation block maturation of dendritic cells, 
and their ability to up-regulate expression of MHC class 
II and B7 co-stimulatory molecules, which are also re-
quired for efficient CD4+ T-cell responses. NF-kB is also 
involved in the regulation of the co-stimulatory molecule 
B7, the ligand for the T-cell co-stimulatory molecule 
ICOS. Collectively, these studies indicate the importance 
of NF-kB in the regulation of accessory cell functions 
which affect adaptive responses34,35. 
 The expression of most f the NF-kB family members 
in T cells indicates that they are likely to be involved in 
T-cell functions. The development of an adaptive T-cell 
response is balanced by the proliferation and expansion of 
antigen-specific T cells during the initiation of the res-
ponse and the loss of excess T cells as the response resol-
ves. In addition, maintenance of long-term memory cells 
is the hallmark of adaptive immunity, and NF-kB has re-
cently been implicated in signals that allow mem ry to 
develop. There are many studies which link NF-kB to T-
cell proliferation, and there are clear links between the ac-
tivation of NF-kB and the expression of cyclin D1, which 
is important in the commitment of the cell to DNA syn-
thesis. Direct evidence for a role of NF-kB in T-cell pro-
liferation is evident from transgenic mice that express the 
degradation-deficient DIkB transgene, which acts as a 
global inhibitor of NF-kB activity, under the control of a 
T-cell-specific promoter. T cells from these mice had se-
verely impaired proliferative responses. Moreover, mice 
lacking the polypeptide p105 precursor of NF-kB1, but 
which express p50, as well as c-Rel–/– mice have impaired 
T-cell proliferative responses. The basis for these prolife-
rative defects is still unclear, although there are many po-
tential explanations35.  
 The recognition that T-cell responses could be broadly 
divided into functional sub ets of Th1 (dominated by the 
production of IFN-g and associated with cell-m diated 
immunity) or Th2 (characterized by production of IL-4, 
IL-5 and associated with humoral immunity), was impor-
tant because it provided a basis for understanding how T 
cells contribute to resistance or susceptibility to different 
types of pathogens. While NF-kB is involved in the pro-
duction of IL-12 required for the generation of Th1 res-
ponses, these transcription factors may also play a direct 
role in the development of polarized T-c ll responses. 
Early studies suggested that although Th1 and Th2 cells 
expressed similar evels of RelA and c-Rel, Th1 cells 
could activate RelA in response to TCR stimulation, 
whereas Th2 cells could not. Evidence of a role for NF-
kB in the production of IFN-g by T cells is provided by 
the description of a functional NF-kB site in the IFN-g 
promoter and by studies that linked the ability of IL-18 to 
activate NF-kB and cause IFN-g production by T cells. 
Moreover, transgenic expr ssion of the degradation-defi-
cient DIkBa mutant in T cells resulted in reduced produc-
tion of IFN-g following TCR stimulation. That mice 
deficient in c-Rel or RelB have dfects in their ability to 
produce IFN-g, implicates these two members in the 
regulation of Th1-cell responses. Regardless of whether 
NF-kB has a direct or indirect role in the regulation of 
IFN-g production, there are sev ral in vivo systems which 
demonstrate a role for NF-kB in disease states in which 
IFN-g plays an important role. Experimental allergic en-
cephalomyelitis is an autoimmune condition mediated by 
a Th1-type T-cell response, and NF-kB1
–/– mice are more 
resistant to the development of this condition. Similarly, 
collagen-induced arthritis is also mediated by Th1 cells, 
an the inhibition f NF-kB in this experimental system 
ameliorates this inflammatory disease53–56.  
 While there are many studies that link NF-kB to the 
development of Th1-type responses, less is known about 
the role of NF-kB in the regulation of Th2-type respon-
es. In vitro studies have r vealed that Th2 cells do acti-
vate NF-kB and that the binding of RelA to sites in the 
IL-4 promoter leads to inhibition of NF-AT binding re-
quired for IL-4 production. Initial studies using transgenic 
mice which express the DIkB mutant in T cells indicated 
that it did not alter the ability of these mice to develop 
Th2-type responses in vivo, although there was some de-
crease in their capacity to produce IL-4 upon primary 
TCR s imulation i  vitro57. Subsequent studies have pro-
vided evidence that NF-kB1 is required for development
 of 
Th2 responses in experimental allergic encephalomyelitis 
and pulmonary inflammation. A potential mechanism that 
explains the requirement for NF-kB1 in Th2 responses is 
increased expression of the transcription factor GATA3, 
which has an important role in differentiation of Th2 cells 
and their production58–60 of IL-4 and IL-5. 
 The IL-1 family (IL-1a/b and IL-18) of proteins 
activate NF-kB and are associated with development of 
Th1 as well as Th2 responses. R lated to those findings 
ar studies, which identified the ST2/T1 protein as a 
homologue of the IL-1 receptor which activates NF-kB 
and is required for the development of Th2-mediated re-
sponses in models of infection and inflammation. How-
ever, gen ration of mice deficient in ST2/T1 has reve led 
that this protein is not essential for Th2 responses. c-Rel 
is required for optimal production of IL-4 as well as in the 
development of Th2 responses associated with allergic 
pulmonary inflammation. Interpretation of many of the 
studies which examine the role of NF-kB in Th1 and Th2 
development is frequently complicated by the linkage bet-
ween NF-kB and its role in proliferation and cell survival, 
which can have a profound influence on the development 
of Th1 and Th2 responses61.  
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B-cell activation and effector function 
The original identification of NF-kB as a nuclear factor 
able to bind to the kB site in the immunoglobulin kappa 
light chain enhancer and the presence of constitutive NF-
kB activity observed in B cells, indicate the importance of 
NF-kB in the control of B-cell functions. This was con-
firmed by multiple studies in which mice deficient in NF-
kB1, NF-kB2, RelA, RelB, c-Rel
 or Bcl-3 or in which the 
DIkB mutant was expressed in B cells, were shown to 
have compromised humoral immune responses. During 
B-cell maturation, the composition of the kB binding acti-
vity changes, with the p50/c-Rel heterodimer being the 
dominant complex present in mature B cells, consistent 
with a requirement for NF-kB1 in immunoglobulin
 class 
switching62.  
 The basis for the defects in humoral i munity in the 
NF-kB-deficient mice is not well understood and may be 
intrinsic to the B-cell compartment or due to compromised 
accessory cell or T-cell functions. For example, NF-kB2 
has functions in cells of the hemopoietic and nonhemo-
poietic lineages that regulate splenic microarchitecture, 
and as a consequence of the disrupted splenic architecture 
and lack of germinal centres, B-cell responses in NF-kB2
–/– 
mice are compromised. There is also a role for RelB in 
the development of radiation-resistant stromal cells, but 
not in bone marrow-derived hemopoietic cells, which are 
required for proper formation of germinal centres. -Rel 
may also have an indirect role in the regulation of B-cell 
functions due to its ability to regulate the production of 
Jagged1, a ligand for Notch receptors, which have a critic l 
role in B-cell proliferation and differentiation. Similarly, 
c-Rel is thought to regulate interferon regulatory factor 4, 
which is required for the ability of the interferon to inhibit 
B-cell proliferation. Nevertheless, there is a di ct role for 
NF-kB in B-cell function, and an understanding of the 
role of individual family members in B-cell function is 
provided by studies which showed that NF-kB1 is re-
quired for survival of quiescent B cells and, in combina-
tion with c-Rel, prevents apoptosis of mitogen-activated 
B cells. Similarly, c-Rel, RelA and RelB are necessary for 
normal proliferative responses upon stimulation through 
the B-cell receptor, CD40 and LPS. Together, these findings 
indicate that the NF-kB proteins are important regulatory 
factors that control the ability of B cells to survive, pro-
gress through the cell cycle and mediate their effector 
functions63–65. 
NF-kB in immuno-inflammatory diseases 
The inflammatory response involves the sequential release 
of mediators and recruitment of circulating leukocytes, 
which become activated at the inflammatory site and re-
lease further mediators. This response is self-limiting and 
resolves through the rel ase of endogenous anti-inflam-
matory mediators and clearance of inflammatory cells. 
The persistent accumulation and activation of leukocytes is 
a hallmark of chronic inflammation. Current approaches 
to the treatment of inflammation rely on the inhibition of 
pro-inflammatory mediator production and of mecha-
nisms that initiate the inflammatory response. However, 
the mechanisms by which the inflammatory response re-
solves might provide new targets in the treatm n  of 
chronic inflammation66,67.  
NF-kB increases the expression of genes for many cyto-
kines, enzymes and adhesion molecules in chronic in-
flammatory diseases. One of them is inducible nitric oxide 
synthase68, the expression of which is increased in airway 
epithelial cells69 and macrophages in patients with asthma70, 
in colonic epithelial cells in patients with ulcerative colitis, 
and in synovial cells in inflamed joints71. I  all chronic 
inflammatory diseases, adhesion molecules recruit in-
flammatory cells such as neutrophils, eosinophils and T 
lymphocytes, from the circulation to the site of inflam-
mation. NF-kB regulates the expression of several genes tha 
encode adhesion molecules such as intercellular adhesion 
molecule 1, vascular-cell adhesion 1 and E-selectin72. 
 Production of IL-1b, TNF-a, IL-6, granulocyte-macro-
phage colony stimulating factor and many chemokines is 
increased in patients with asthma, RA, psoriasis and in-
flammatory bowel disease. All these cytokines have an 
important role in the inflammatory process. IL-1b and 
TNF-a may influence the severity of the disease, possibly 
by the persistent activation of NF-kB. The treatment of 
patients with RA with antibodies to TNF-a can control 
refractory disease73–75. 
Role in rheumatoid arthritis 
NF-kB has been shown to play diverse roles in the initia-
tion and perpetuation of rheumatoid arthritis. Activated 
NF-kB is a common feature in human rheumatoid arthritis 
synovium and in various animal models of rheumatoid ar-
thritis such asdjuvant arthritis in rats, collagen-i duced 
arthritis in mice, and streptococcal ell wall-induced ar-
thritis in rats. Studies have shown that NF-kB activation 
increases expression of inflammatory molecules in syno-
viocytes and protects cells against TNF-a and Fas ligand-
induced apoptosis. Studies with cultured cells in which 
NF-kB was inactivated or over-expressed showed a pro-
tective function of NF-kB against the cytotoxicity of TNF 
and other agents. NF-kB activation leads to expression of 
several genes that prevent apoptosis in a number of cell 
types. Inhibition of NF-kB induces apot sis in TNF-a or 
IL-1b-stimulated synovial cells and prevents their hyper-
proliferation and in vivo suppression of NF-kB enhanced 
apoptosis in the synovium of experimentally induced arthritis 
of rats. Intra-articular administration of NF-kB ‘decoy’ 
oligodeoxynucleotides prevented the recurrence of strep-
tococcal cell wall arthritis in treated joints, suggesting the 
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beneficial effects of local inhibition of NF-kB in arthri-
tis76–78. 
Role in allergic diseases 
Although there are many similarities between the inflam-
matory responses in patients with arthritis, asthma, inflam-
matory bowel disease and other inflammatory diseases, 
there are also important differences in the type of inflam-
matory cells involved and in the perpetuation of inflam-
mation. These differences may relate to the secretion of 
specific cytokines such as IL-5, which in patients with 
asthma promotes eosinophilic inflammation. NF-kB should 
be considered as an amplifying and perpetuating mecha-
nism that can exaggerate the disease-sp cific inflamma-
tory process through the coordinated activation of several 
inflammatory genes. Thus, the presence of IL-5 al ne re-
sults in relatively little accumulation of eosinophils i  the 
tissue, but action of IL-5 can be amplified by local injec-
tion of the eosinophil-specific chemokine, eotaxin. The 
transcription of the genes for both IL-5 and eotaxin is in-
fluenced by NF-kB66,67. 
NF-kB in malignancies 
Further, several tumour systems have constitutive activa on 
of NF-kB. This enhanced NF-kB activity allows tumour 
cells to constitutively express angiogenic and angiostatic 
chemokines, cytokines such as VEGF, IL-1 and IL-6, 
which affect tumour growth and escape from apoptosis. 
The expression of CCL5 in melanoma and breast cancer 
correlates with the metastatic capacity of the tum ur and 
the expression of CCL5 is induced by NF-kB. Down-
modulation of CCL5 through the inhibition of NF-kB of-
fers promise for therapeutic intervention. Researchers 
have observed that once the expression of CXCL1 and 
CXCL8 has been induced, these secreted chemokines 
lead to positive feedback on the activation of NF-kB. En-
dogenous activation of NF-kB in melanoma tumour cells 
can be inhibited by 50% with an antibody specific for 
CXCL1, indicating that chemokine autocrine loops may 
be important for perpetuating the constitutive activation 
of NF-kB in melanoma. In addition, cytokines or altera-
tions in the signal-transduction pathway may also con-
tribute to the dysregulation of NF-kB in melanoma79. 
NF-kB in oxidative stress 
Recently, a possible role for oxidative stress in the activa-
tion of NF-kB has been implicated. NF-kB is recognized 
as a redox-sensitive transcription factor, and has been im-
plicated in cellular response to oxidative stress80. Molecular 
oxygen presents a paradox to aerobic organisms in that it 
is both essential and at the same time extremely toxic. Al-
though non-reactive in its ground state, molecular oxygen 
is reduced via normal metabolic processes, yielding a variety 
of highly reactive oxygen intermediates (ROIs) in the 
process. These ROIs include the superoxide radical (O2
–), 
hydrogen peroxide (H2O2), and the most po ent oxidant, 
the hydroxyl radical (OH). ROIs can readily cause oxida-
tive damage to various biological macromolecules result-
ing in DNA damage, DNA strand breaks, oxidation of 
key amino acid side chains, formati n of protein–protein 
cross-links, oxidation of the polypeptide backbone result-
ing in protein fragmentation, and lipid peroxidation81,82. 
These oxidation-induced lesions have been suggested to 
contribute to various diseases and degenerative processes 
such as aging, carcinogenesis, immunodeficiencies and 
cardiovascular diseases and have also been implicated in 
the pathogenesis of most inflammatory diseases, including 
cerebral vascular disease. Since pro-inflammatory mole-
cules are involved in the pathogenesis of these inflamma-
tory diseases, interactions between ROS and NF-kB 
might be a component of the intracellular signalling proc-
ess that leads to activation. 
 In this regard, the mouse hepatocyte iNOS promoter 
has NF-kB-binding sites at nt –1044 to nt –1034 and at nt 
–114 to nt –104, which are considered to be critical for 
iNOS expression in response to pro-inflammatory cyto-
kine stimulation. Activity of the transcription factor NF-
kB is redox-modulated and peroxide-mediated oxidative 
stress induces hyper-acetylation and enhanced accessibility 
of the restriction enzyme to nt-114 NF-kB region. Thus, 
chromatin structural changes activate the NF-kB site and 
increase interleukin-1b-stimulated iNOS expression in 
the pr sence of oxidative stress83. 
 Four areas of evidence indicate that NF-kB activation 
is linked to the generation of ROS. First, treatment with 
hydrogen peroxide directly activates NF-kB in some 
cells. In addition, over-expression of superoxide dismu-
tase, the enzyme that converts superoxide anion to hydro-
g n peroxide, enhances the TNF-induced activation of 
NF-kB. Second, most of the known stimuli for NF-kB acti-
vation, including LPS, TNF-a, and IL-1b, produce oxidative 
stress in cells. Third, treatment with N-acetylcysteine, a-
lipoic acid, membrane-permeable hydroxyl scavengers, 
metallothionein and the iron chelator, PDTC, blocks NF-
kB activation induced by a wide variety of stimuli. These 
antioxidants are also effective in attenuating inflamma-
tion in rodent models of neutrophilic lung and cerebral 
inflammation. Fourth, over-exp ession of catalase or glu-
tathione peroxidase, enzymes that scavenge hydrogen 
peroxide as well as organic peroxides using gl tathione 
(GSH) as the electron donor, ihibits the cytokine- du-
ced activation of NF-kB. Further, over- xpression of g-
glutamylcysteine synthetase, the rate-limiting enzyme for 
GSH synthesis attenuates TNF-a-induced NF-kB activation. 
These observations, toge her, suggest that ROS act as a 
common second messenger following cellular exposure to 
agents that induce NF-kB activation84–87. 
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Table 3. Therapeutic targetting of NF-kB 
Inhibitors of Rel/NF-kB Molecule Mechanism 
Degradation-resistant  
 IkB proteins 
*IkBa mutant/ 
 super- epressor 
Sequesters NF-kB in the cytoplasm and thus prevents the induction of specif c NF-kB  
 target genes 
Glucocorticoids Dexamethasone  
Prednisone 
Induce expression of IkBa to enhance the cytosolic retention of NF-kB  
Maintain NF-kB in an inactive cytoplasmic complex so that the expression of genes  
 involved in the pathogenesis of the immune response is reduced 
Reduce NF-kB-mediated transcriptional activity without al ering IkB protein levels or 
 the nuclear translocation of NF-kB 
Direct protein–protein interactions between the activated glucocorticoid receptor and  
 NF-kB can also prevent activtion of this pathway 
Competition between NF-kB and the glucocorticoid receptor for limiting amounts of  
 the coactivators CREB-binding protein (CBP) and steroid receptor coactivator-1  
 (SRC-1) 
Glucocorticoid receptor directly disrupts p65 interactions with he basal transcription  
 machinery, by direct interactions either with p65 or with components of the basal  
 transcription complex 
NSAIDs Aspirin  
Sodium salicylate 
Sulfasalazine 
Sulindac 
Specific inhibition of ATP-binding to IKKb. Thus, IKKb-dependent phosphorylation  
 of IkBb is markedly reduced, preventing its degradation by the pr teasome and  
 activation of the NF-kB pathway 
Suppression of IkBa phosphorylation and its subsequent degradation 
Activation of the NF-kB pathway by inhibiting IKK activity 
Immunosuppressive agents CsA 
Tacrolimus (FK-506) 
CsA serves as a noncompetitive inhibitor of the chymotrypsin-like activity of the 20S  
 proteasome and thus prevents IkBa degradation and activation of the NF-kB  
 pathway 
Specifically blocks translocation of c-Rel rom the cytoplasm to the nucl us 
FK-506 blocks both antigen receptor-induced and phorbol ester and ionomycin- 
 induced c-Rel nuclear translocation in both B and T cells; neither RelB induction  
 nor p50 expression is altered by FK-506 treatment 
CyPGs  Directly inhibits NF-kB activity by modification of a cysteine residue in the  
 activation  loop of IKKb 
Inhibition of proteasome  
 function prevents IkB  
 degradation 
Peptide aldehydes: 
MG101, MG132, and  
 MG115 
Lactacystin 
 
Boronic acid peptides:  
 PS-341 
Inhibitors of proteasome function reduce the degradation of IkB to prevent activation  
 of the NF-kB pathway 
 
Block protein degradation activity by acylating a threonine residue in one of the key  
 proteasome subunits 
Potent inhibitors of proteasome function 
Natural products Flavonoids 
Rsveratrol 
 
 
Myricetin, etc. 
Ability to reduce IKK activity 
Inhibit NF-kB activity and induce apoptosis in transformed cells, which may  
 contribute to the ability of red wine to reduce mortality from coronary heart  
 diseases and certain cancers 
Has strong inhibitory effects on iNOS expression and NO generation in activated  
 macrophages 
*Is IkBa protein with mutations at serine residues 32 and 36 is not subject to phosphorylation by IKK and is not degraded by the proteasome. 
Cyclopentenone prostaglandins, CyPGs; Cyclosporin A, CsA; Nonsteroidal anti-inflammatory drugs, NSAIDs. 
 
 However, the common point of the interaction between 
ROS on the NF-kB activation pathway is unknown. The 
most likely scenario is that ROS promote the activation 
pathway by activating a critical redox-sensitive kinase, 
probably NIK or the IKK signals, since these molcules 
lead to phosphorylation of critical serine residues in IkB,
resulting in the liberation of cytoplasmic RelA/p50 het-
erodimers. However, the exact biochemical nature of the 
interaction between ROS and kinase activity of IKKa, 
IKK b, or NIK has not yet been delineated. It is possible, 
though not proven, that the redox state of critical cysteine 
residues could reversibly modulate kinase activity and 
regulate NF-kB activation. 
NF-kB as a therapeutic target 
Consistent with the pivotal role of NF-kB in inflammation, 
it is an attractive target for various anti-inflammatory 
compounds (Table 3). It can be blocked at various steps, 
including its activation through different pathways, its 
translocation to the nucleus and its binding to DNA. Indeed 
the most commonly used compounds like aspirin and other
nonsteroidal anti-i flammatory drugs do block NF- B88. 
They inhibit IKKb-dependent phosphorylation of IkBa, thus 
preventing its degradation and subsequent activation of 
NF-kB. 
 Glucocorticoids such as prednisone are one of the most 
potent anti-inflammatory agents used in therapy, and they 
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cause transcriptional repression of several cytokines and 
adhesion molecules. While glucocorti ids down-regulate 
the expression of genes relevant during inflammation, 
NF-kB/Rel proteins function as important positive regulators 
of these genes. Glucocorticoids inhibit NF-kB at multiple 
steps, including induction of IkBa leading to enhanced 
binding to NF-kB and retention in the cytoplasm, direct 
interaction of activated glucocorticoid receptor (GnR) in 
cytosol with NF-kB, competition between GnR and NF-
kB for coactivators and inhibition of basal transcrip ional 
complex89. Even other anti-inflammatory compounds used in 
therapy of rheumatoid arthritis have been shown to inhi-
bit NF-kB90,91. For example, gold compounds block NF-
kB activation. Sulphasalazine92 hibits TNF-a-induced 
NF-kB activation by decreasing IkBa phosphorylation 
like NSAIDs. Other immunosuppressive drugs like cyclo-
sporin and tacrolimus also inhibit the NF-kB pathway93.  
 Other ways to block NF-kB is to use synthetic peptides 
that inhibit proteosome degra ation of IkB94, anti-cyto-
kine therapy to prevent cytokine-mediated activation and 
introduction of IkBa super- epressor. Recent studies95 
have shown that during the resolution of inflammation, 
cyclopentenate prostaglandins (cyPG) induced NF-kB ac-
tivation in leukocytes and protracted the inflammatory re-
sponse. Notably, the sel ctive COX2 inhibitor NS398 did 
not reduce NF-kB DNA-binding activity in leukocytes, 
which suggests that cyPGs may act downstream of NF-kB 
in the resolution of inflammation in vivo. There are con-
cerns with the use of these inhibitors of NF-kB, which 
may have effects independent of the NF-kB pathway. 
However, use of inhibitors allows modulation of NF-kB 
at specific stages of the inflammatory response. It is important
to note that such inhibitors may prevent the proper reso-
lution of inflammation in vivo. Thus, the identification of 
NF-kB as a key player in the pathogenesis of inflamma-
tion suggests that NF-kB-targetted therapeutics might be 
effective in diseases like RA, inflammatory bowel diseas ,
and various other animal models of inflammatory dis-
ease96,97. 
 The ultimate benefit of such targeted therapy will depend 
on the delicate balance between suppression of inflamma-
tion and interference with normal cellular functions. U-
fortunately, currently available molecular genetics tools 
do not allow modulation of the NF-kB pathway at different 
stages of the inflammatory response in vivo. It is to be 
hoped that the development of such tools will help define 
the role of NF-kB pathway in iflammation. 
Conclusion  
NF-kB is a central regulator of innate and adaptive immune 
responses. This function is accomplished through the in-
duction of genes, some of which promote inflammation, 
leukocyte migration and activation, whereas others act as 
potent inhibitors of apoptosis. Finally, the role of NF-kB 
i  modulating the expr ssion of different cytokines strongly 
supports its proposed role as a coordinating element in 
the body’s response to stress, infection or inflammation. 
It may be desirable under certain circumstances, such as 
during cancer therapy, to dissociate the immunoregula-
tory function of NF-kB from its anti-apoptotic activity. 
However, this may not be easily achieved without a better 
understanding of all the mechanisms involved in the acti-
vation of specific and physiologically relevant NF-kB 
targets. The complete understanding of NF-kB gene regu-
lation is therefore a major challenge for future research. 
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